Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
2.560
+0.190 (8.02%)
At close: May 15, 2025, 4:00 PM
2.380
-0.180 (-7.03%)
After-hours: May 15, 2025, 6:51 PM EDT
Taysha Gene Therapies Market Cap
Taysha Gene Therapies has a market cap or net worth of $549.53 million as of May 15, 2025. Its market cap has increased by 19.93% in one year.
Market Cap
549.53M
Enterprise Value
492.49M
1-Year Change
19.93%
Ranking
Category
Stock Price
$2.56
Market Cap Chart
Since the IPO on September 24, 2020, Taysha Gene Therapies's market cap has decreased from $690.43M to $549.53M, a decrease of -20.41%. That is a compound annual growth rate of -4.80%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 14, 2025 | 485.98M | 37.07% |
| Dec 31, 2024 | 354.55M | 7.14% |
| Dec 29, 2023 | 330.92M | 134.50% |
| Dec 30, 2022 | 141.12M | -68.52% |
| Dec 31, 2021 | 448.22M | -55.28% |
| Dec 31, 2020 | 1.00B | 45.15% |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 642.38B |
| Johnson & Johnson | 352.15B |
| AbbVie | 313.43B |
| Novo Nordisk | 288.64B |
| UnitedHealth Group | 279.41B |
| Abbott Laboratories | 223.67B |
| Novartis AG | 208.47B |
| AstraZeneca | 206.71B |